Acne biotech Foamix Pharmaceuticals files for a $75 million IPO

By
A A A

Foamix Pharmaceuticals, an Israeli biotech developing topical foam treatments for moderate-to-severe acne, filed on Wednesday with the SEC to raise up to $75 million in an initial public offering. The company expects to enter Phase 3 trials for its lead candidate, a 4% minocycline foam formulation, in 2015.

The Weizmann Science Park, Israel-based company, which was founded in 2003 and booked $3 million in licensing agreements for the 12 months ended June 30, 2014, plans to list on the NASDAQ under the symbol FOMX. Foamix initially filed confidentially on May 20, 2014. Barclays and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks:

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

30,613,835
  • $5.67 ▼ 14.61%
18,713,066
  • $17.01 ▲ 1.43%
11,294,536
  • $42.725 ▲ 0.32%
6,857,543
  • $12.7693 ▼ 17.83%
6,670,752
  • $102.03 ▲ 0.44%
6,629,659
  • $4.294 ▲ 10.67%
6,101,971
  • $26.295 ▲ 0.94%
5,665,516
  • $6.80 ▲ 0.44%
As of 9/18/2014, 10:02 AM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com